Bank of Montreal
RVNC

Bank of Montreal’s Revance Therapeutics, Inc. RVNC Stock Holding History

Bank of Montreal’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-5,700
Closed -$50.9K – 4434
2023
Q4 		$50.9K Hold
5,700
– – ﹤0.01% 3558
2023
Q3 		$102K Buy
+5,700
New +$110K ﹤0.01% 3273
2021
Q2 		– Sell
-4,000
Closed -$111K – 5061
2021
Q1 		$111K Sell
4,000
-10,000
-71% -$277K ﹤0.01% 3346
2020
Q4 		$405K Sell
14,000
-38,700
-73% -$1M ﹤0.01% 2828
2020
Q3 		$1.34M Buy
+52,700
New +$1.38M ﹤0.01% 1834

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of Montreal's RVNC Position: Q1 2024 in Review

Bank of Montreal sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2024, closing a stake of 6,474 shares — an estimated $57.8K sold.

Bank of Montreal first reported a position in RVNC in Q2 2014 and held it in 19 quarters. The position peaked at $1.52M in Q1 2023. 188 funds tracked by Wall St. Rank hold RVNC as of Q1 2024.

  • Bank of Montreal reported no remaining Revance Therapeutics, Inc. position as of Q1 2024 after selling out during the quarter.
  • Bank of Montreal sold 6,474 Revance Therapeutics, Inc. shares in Q1 2024, an estimated $57.8K.
  • Bank of Montreal first reported a position in Revance Therapeutics, Inc. in Q2 2014 and held it in 19 quarters.
  • Bank of Montreal's Revance Therapeutics, Inc. position peaked at $1.52M in Q1 2023.
  • 188 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2024.

Based on Bank of Montreal's 13F filing for Q1 2024, filed 13 May 2024.